Literature DB >> 3263233

False positive ELISA tests for anticardiolipin antibodies in sera from patients with repeated abortion, rheumatologic disorders and primary biliary cirrhosis: correlation with elevated polyclonal IgM and implications for patients with repeated abortion.

S Cowchock1, J Fort, S Munoz, R Norberg, W Maddrey.   

Abstract

Non-specific binding in an ELISA test for antibodies to cardiolipin (ACA) was investigated in sera from patients with primary biliary cirrhosis, rheumatological disorders, and repeated abortion. Binding to wells without phospholipid was most frequent in ELISA assay for IgM class ACA and correlated with levels of serum polyclonal IgM in patients with repeated abortion and rheumatologic disorders (r = 0.79, 0.76). Using added polyclonal IgM we demonstrated that the increase in non-specific binding was most significant when levels of ACA were low; subtraction of binding to the unoccupied well over-corrected specific antibody estimates when a high affinity antibody was present. Absorption studies on three sera suggest that this 'non-specific' binding includes low affinity antibody binding. Elevated levels of polyclonal IgM in sera from patients with repeated abortion may account for some reports of elevated IgM class antibodies in other ELISA assays. The prevalence of a positive test for ACA in a sequential series of 412 such patients was reduced to 6.1% (95% confidence limits 4-9%) after subtraction of non-specific binding.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263233      PMCID: PMC1541597     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Anticardiolipin response in acute infections.

Authors:  O Vaarala; T Palosuo; M Kleemola; K Aho
Journal:  Clin Immunol Immunopathol       Date:  1986-10

2.  Anticardiolipin antibodies in pregnant patients with systemic lupus erythematosus.

Authors:  R Lenzi; J H Rand; H Spiera
Journal:  N Engl J Med       Date:  1986-05-22       Impact factor: 91.245

3.  Immunoglobulins in spontaneous abortion and ectopic pregnancy.

Authors:  R T O'Neill; S B Ambacher; J B Smith
Journal:  Obstet Gynecol       Date:  1970-08       Impact factor: 7.661

4.  IgM gammopathy and the lupus anticoagulant syndrome in habitual aborters.

Authors:  N Gleicher; J Friberg
Journal:  JAMA       Date:  1985-06-14       Impact factor: 56.272

5.  Circulating antisperm antibodies in recurrently aborting women.

Authors:  G G Haas; K Kubota; J F Quebbeman; A Jijon; A C Menge; A E Beer
Journal:  Fertil Steril       Date:  1986-02       Impact factor: 7.329

Review 6.  Clinical and prognostic relevance of different mitochondrial antibody profiles in primary biliary cirrhosis (PBC).

Authors:  P A Berg; R Klein
Journal:  Mol Aspects Med       Date:  1985

7.  Anticardiolipin antibodies in patients with rheumatic diseases.

Authors:  J G Fort; F S Cowchock; J L Abruzzo; J B Smith
Journal:  Arthritis Rheum       Date:  1987-07

8.  Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results.

Authors:  S Loizou; J D McCrea; A C Rudge; R Reynolds; C C Boyle; E N Harris
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

9.  Antibodies to phospholipids and nuclear antigens in patients with repeated abortions.

Authors:  S Cowchock; J B Smith; B Gocial
Journal:  Am J Obstet Gynecol       Date:  1986-11       Impact factor: 8.661

10.  Spontaneous recurrent fetal wastage and autoimmune abnormalities: a study of fourteen cases.

Authors:  J P Clauvel; C Tchobroutsky; F Danon; Y Sultan; L Intrator; J C Brouet
Journal:  Clin Immunol Immunopathol       Date:  1986-06
View more
  13 in total

Review 1.  Testing for and clinical significance of anticardiolipin antibodies.

Authors:  S W Reddel; S A Krilis
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome.

Authors:  J Ordi-Ros; J Villarreal; F Monegal; S Sauleda; I Esteban; M Vilardell
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

3.  Falsely normal C4 in a case of acquired C1 esterase inhibitor deficiency.

Authors:  Andrew McLean-Tooke; Catherine Stroud; Anne Sampson; Gavin Spickett
Journal:  J Clin Pathol       Date:  2007-05       Impact factor: 3.411

4.  Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds.

Authors:  T Qamar; A E Gharavi; R A Levy; M D Lockshin
Journal:  J Clin Immunol       Date:  1990-07       Impact factor: 8.317

5.  Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients.

Authors:  R Cervera; J Font; C Paré; M Azqueta; F Pérez-Villa; A López-Soto; M Ingelmo
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

6.  Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations.

Authors:  J Font; R Cervera; A Lopez-Soto; L Pallares; X Bosch; S Ampurdanes; F J Casals; M Ingelmo
Journal:  Clin Rheumatol       Date:  1989-12       Impact factor: 2.980

7.  Anti-cardiolipin antibodies and HIV infection.

Authors:  C Maclean; P J Flegg; D C Kilpatrick
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

Review 8.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

9.  Prevalence of antiphospholipid antibodies in patients with fetal loss.

Authors:  H J Out; H W Bruinse; G C Christiaens; M van Vliet; J F Meilof; P G de Groot; R J Smeenk; R H Derksen
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

10.  Systemic lupus erythematosus in the elderly: clinical and immunological characteristics.

Authors:  J Font; L Pallarés; R Cervera; A López-Soto; M Navarro; X Bosch; M Ingelmo
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.